Table 3.
Clinical and hemodynamic effect of BPA in anatomically inoperable patients (d-CTEPH) and inoperable patients because of comorbidities or patients’ refusal (p-CTEPH).
| Anatomically Inoperable (d-CTEPH Group) (n = 54) |
Inoperable Because of Comorbiditie (p-CTEPH Group) (n = 16) |
|||||
|---|---|---|---|---|---|---|
| Before | p | After | Before | p | After | |
| HR (bpm) | 78 ± 15 | <0.001 | 69 ± 13 | 75 ± 16 | 0.04 | 67 ± 9 |
| BP systolic (mmHg) | 126 ± 24 | 0.24 | 121 ± 16 ** | 140 ± 30 | 0.55 | 142 ± 25 ** |
| BP diastolic (mmHg) | 76 ± 14 | <0.001 | 70 ± 10 * | 77 ± 14 | 0.88 | 77 ± 9 * |
| WHO class (I–II/III–IV) | 20%/80% | <0.001 | 77%/23% | 19%/81% | 0.02 | 79%/21% |
| 6mWT (m) | 384 ± 131 | <0.001 | 453 ± 115 * | 300 + 164 | 0.11 | 355 ± 112 * |
| NT-pro-BNP (pg/mL) (median) (IQR) |
1380 (330–3294) |
<0.001 |
157 (77–448) |
1288 (754–2870) |
<0.001 |
255 (203–897) |
| mRAP (mmHg) | 9.4 ± 4.7 | <0.001 | 5.6 ± 3.4 | 8.4 ± 3.3 | 0.05 | 5.6 ± 2.5 |
| PAPs (mmHg) | 82.1 ± 18.3 | <0.001 | 54.1 ± 17.7 | 80.0 ± 18.5 | 0.001 | 52.9 ± 10.8 |
| PAPd (mmHg) | 29.3±6.7 | <0.001 | 25.8 ± 9.1 * | 25.8 ± 9.1 | 0.02 | 16.9 ± 3.9 * |
| PAPm (mmHg) (median) (IQR) |
49.0 ± 10.0 49 (43–55) |
<0.001 | 31.3 ± 9.3 31 (25–36) |
47.1 ± 10.1 46 (41–52) |
0.001 | 31.2 ± 5.6 29 (27–36) |
| PCWP (mmHg) | 9.7 ± 2.8 | 0.65 | 9.4 ± 3.3 * | 10.4 ± 2.3 | 0.44 | 12.1 ± 4.2 * |
| CO (L/min) | 4.94 ± 1.65 | 0.06 | 5.43 ± 1.53 | 5.03 ± 1.39 | 0.43 | 5.47 ± 1.17 |
| CI (L/min*m2) | 2.72 ± 0.78 | 0.04 | 2.95 ± 0.80 | 2.88 ± 0.78 | 0.50 | 2.96 ± 0.67 |
| SV (ml) | 65 ± 21 | <0.001 | 79 ± 20 | 68 ± 18 | 0.01 | 83 ± 18 |
| Art Sat. O2(%) | 93.8 ± 3.1 | 0.01 | 95.2 ± 3.8 | 93.7 ± 3.1 | 0.45 | 93.9 ± 3.6 |
| MV Sat.O2(%) | 65.7 ± 6.7 | <0.001 | 72.5 ± 6.4 | 63.6 ± 7.0 | 0.01 | 70.9 ± 6.1 |
| PVR (dynes*s*cm−5) (median) (IQR) |
713 ± 305 683 (479–935) |
<0.001 | 345 ± 176 286 (223–420) |
628 ± 263 556 (429–862) |
0.001 | 288 ± 87 278 (245–303) |
| CPa (mL/mmHg) | 1.38 ± 0.72 | <0.001 | 2.39 ± 0.93 | 1.50 ± 0.89 | 0.01 | 2.39 ± 0.61 |
| Absolute change of mPAP(mmHg) | −17.1 ± 9.4 | −15.9 ± 12.0 | ||||
| % decrease of mPAP (%) | −35 ± 16 | −31 ± 19 | ||||
| % decrease of PVR (%) | −46 ± 23 | −46 ± 19 | ||||
HR–heart rate; BP–blood pressure; WHO–World Health Organisation; 6mWT–6 min walk test; NT-proBNP–N-terminal probrain natriuretic peptide; mRAP–mean right atrial pressure; PAPs–systolic pulmonary artery pressure; PAPd–diastolic pulmonary artery pressure; PAPm–mean pulmonary artery pressure; PCWP–pulmonary capillary wedge pressure; CO–cardiac output; CI–cardiac index; SV–stroke volume; Art.SatO2–arterial oxygen saturation; MvSatO2–mixed venous oxygen saturation; PVR–pulmonary vascular resistance; CPa–pulmonary artery compliance. Data are presented as means ± standard deviations or median and (interquartile range); * p < 0.05; ** p < 0.01 for comparisons between anatomically inoperable and inoperable because of comorbidities.